Active Filter(s):
Details:
The collaboration aims to help evaluate therapeutic response and provide molecular insights for Rutgers Cancer Institute trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Lead Product(s): Doxorubicin Hydrochloride,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Rutgers Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023